CY1119048T1 - Παραγωγα στυρυλοπυριδινης και η χρηση τους για συνδεση κι απεικονιση πλακων αμυλοειδους - Google Patents

Παραγωγα στυρυλοπυριδινης και η χρηση τους για συνδεση κι απεικονιση πλακων αμυλοειδους

Info

Publication number
CY1119048T1
CY1119048T1 CY20171100664T CY171100664T CY1119048T1 CY 1119048 T1 CY1119048 T1 CY 1119048T1 CY 20171100664 T CY20171100664 T CY 20171100664T CY 171100664 T CY171100664 T CY 171100664T CY 1119048 T1 CY1119048 T1 CY 1119048T1
Authority
CY
Cyprus
Prior art keywords
stylyloid
styrylpyridine
release
products
connection
Prior art date
Application number
CY20171100664T
Other languages
English (en)
Inventor
Hank F Kung
Mei-Ping Kung
Original Assignee
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennsylvania filed Critical The Trustees Of The University Of Pennsylvania
Publication of CY1119048T1 publication Critical patent/CY1119048T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η εφεύρεση αυτή σχετίζεται με μια μέθοδο απεικόνισης αποθέσεων αμυλοειδούς και με ενώσεις στυρυλοπυριδίνης, και μεθόδους παρασκευής ραδιοεπισημασμένων ενώσεων στυρυλοπυριδίνης χρήσιμων για απεικόνιση αποθέσεων αμυλοειδούς. Αυτή η εφεύρεση επίσης σχετίζεται με ενώσεις, και μεθόδους παρασκευής ενώσεων για αναστολή της συσσωμάτωσης πρωτεϊνών αμυλοειδούς για σχηματισμό αποθέσεων αμυλοειδούς, και μια μέθοδο χορήγησης ενός θεραπευτικού μέσου σε αποθέσεις αμυλοειδούς.
CY20171100664T 2006-03-30 2017-06-22 Παραγωγα στυρυλοπυριδινης και η χρηση τους για συνδεση κι απεικονιση πλακων αμυλοειδους CY1119048T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78715606P 2006-03-30 2006-03-30
EP07753982A EP1999109B1 (en) 2006-03-30 2007-03-26 Styrylpyridine derivatives and their use for binding and imaging amyloid plaques

Publications (1)

Publication Number Publication Date
CY1119048T1 true CY1119048T1 (el) 2018-01-10

Family

ID=38326579

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20121100225T CY1113048T1 (el) 2006-03-30 2012-03-07 Παραγωγα στυρυλοπυριδινης και η χρηση τους για συνδεση κι απεικονιση πλακων αμυλοειδους
CY2013024C CY2013024I2 (el) 2006-03-30 2013-06-27 Παραγωγα στυρυλοπυριδινης και η χρηση τους για συνδεση κι απεικονιση πλακων αμυλοειδους
CY20171100664T CY1119048T1 (el) 2006-03-30 2017-06-22 Παραγωγα στυρυλοπυριδινης και η χρηση τους για συνδεση κι απεικονιση πλακων αμυλοειδους

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20121100225T CY1113048T1 (el) 2006-03-30 2012-03-07 Παραγωγα στυρυλοπυριδινης και η χρηση τους για συνδεση κι απεικονιση πλακων αμυλοειδους
CY2013024C CY2013024I2 (el) 2006-03-30 2013-06-27 Παραγωγα στυρυλοπυριδινης και η χρηση τους για συνδεση κι απεικονιση πλακων αμυλοειδους

Country Status (34)

Country Link
US (3) US7687052B2 (el)
EP (3) EP2363392B1 (el)
JP (1) JP5290954B2 (el)
KR (1) KR101376807B1 (el)
CN (1) CN101522624B (el)
AT (1) ATE539060T1 (el)
AU (1) AU2007243712B2 (el)
BR (1) BRPI0710225B1 (el)
CA (1) CA2644530C (el)
CR (1) CR10329A (el)
CY (3) CY1113048T1 (el)
DK (2) DK2363392T3 (el)
EA (1) EA017898B1 (el)
EC (1) ECSP088783A (el)
ES (2) ES2378785T3 (el)
FR (1) FR13C0034I2 (el)
GT (1) GT200800201A (el)
HR (2) HRP20120135T1 (el)
HU (2) HUE032660T2 (el)
IL (1) IL193567A (el)
LT (1) LT2363392T (el)
LU (1) LU92232I2 (el)
MX (1) MX2008012527A (el)
NO (2) NO342090B1 (el)
NZ (1) NZ570887A (el)
PL (2) PL1999109T3 (el)
PT (2) PT2363392T (el)
RS (2) RS52222B (el)
SG (1) SG173338A1 (el)
SI (2) SI2363392T1 (el)
TW (1) TWI399366B (el)
UA (1) UA97802C2 (el)
WO (1) WO2007126733A2 (el)
ZA (1) ZA200807955B (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE539060T1 (de) * 2006-03-30 2012-01-15 Univ Pennsylvania Styrylpyridinderivate und ihre verwendung zur bindung und abbildung von amyloider plaque
JP5322180B2 (ja) * 2007-07-04 2013-10-23 国立大学法人東北大学 フッ素およびヒドロキシ基で置換されたアルコキシ基を有するｐｅｔプローブ
US8557222B2 (en) 2008-04-04 2013-10-15 Avid Radiopharmaceuticals, Inc. Radiopharmaceutical imaging of neurodegenerative diseases
DK2381967T3 (en) * 2008-12-31 2017-03-27 Avid Radiopharmaceuticals Inc Synthesis of 18F-radiolabelled styryl pyridines from tosylate precursors and stable pharmaceutical compositions thereof
JP2012532164A (ja) * 2009-07-10 2012-12-13 バイエル ファーマ アクチエンゲゼルシャフト 放射性トレーサーの精製のための低‐中圧液体クロマトグラフィーの使用
US20120263646A1 (en) 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
CA2785576C (en) * 2009-12-23 2017-12-05 Piramal Imaging Sa Formulations suitable for pet imaging with hydrophobic pet agents
WO2011141515A1 (en) 2010-05-14 2011-11-17 Bayer Pharma Aktiengesellschaft Diagnostic agents for amyloid beta imaging
JP2013532136A (ja) 2010-06-04 2013-08-15 ピラマル イメージング ソシエテ アノニム Ｆ−１８標識アミロイド・ベータ・リガンドの製造方法
TWI504414B (zh) 2010-06-04 2015-10-21 Bayer Schering Pharma Ag 生產Ｆ－１８標記之Ａβ配位體之方法
EA201201647A1 (ru) * 2010-06-04 2013-05-30 Пирамаль Имэджинг Са Способ получения f-18 меченных лигандов бета-амилоида
CA2801530C (en) 2010-06-04 2017-09-12 Piramal Imaging Sa Method for production of f-18 labeled amyloid beta ligands
CN101891674B (zh) * 2010-06-24 2012-11-14 山东大学 4-苯乙烯基吡啶类化合物及其制备方法与应用
EP3263136A1 (en) * 2010-10-12 2018-01-03 Mayo Foundation for Medical Education and Research Imaging of meningiomas using stilbene, or biphenylalkyne derivatives
US20140079635A1 (en) * 2011-03-30 2014-03-20 Case Western Reserve University Molecular probes for detecting lipid composition
CA2831331C (en) * 2011-04-21 2019-10-15 The Regents Of The University Of California Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles
BR112014009013A2 (pt) 2011-10-19 2017-05-02 Piramal Imaging Sa método melhorado para a produção de ligandos aß rotulados por f-18
EP2836241B1 (en) 2012-04-10 2019-02-20 Lantheus Medical Imaging, Inc. Radiopharmaceutical synthesis methods
JP6099045B2 (ja) * 2013-04-30 2017-03-22 国立大学法人京都大学 トリアゾロピリミジン誘導体化合物
JP6041751B2 (ja) * 2013-05-07 2016-12-14 日本メジフィジックス株式会社 スチリルピリジン誘導体化合物
JP2014218454A (ja) * 2013-05-07 2014-11-20 日本メジフィジックス株式会社 スチリルピリジン誘導体化合物
CN103645254B (zh) * 2013-11-28 2015-01-07 江苏省原子医学研究所 一种Aβ斑块显像剂前体AV45的含量分析方法
PT3143011T (pt) * 2014-05-13 2021-04-26 Hoffmann La Roche Compostos heterocíclicos deuterados e a sua utilização como agentes de imagiologia
EP3337475A4 (en) * 2015-08-18 2019-04-10 The Regents of The University of California NITROXIDE WITH AMYLOID BINDING AGENT FOR IMAGING AND THERAPEUTIC USES
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
CN109400615B (zh) * 2017-08-18 2021-07-16 上海交通大学医学院附属新华医院 一种靶向β-淀粉样蛋白的香豆素类化合物及其制备与应用
CN108299287A (zh) * 2018-01-02 2018-07-20 北京师范大学 与Aβ斑块具有高亲和力的N2S2类吡啶基苯乙烯化合物
CN114805190A (zh) * 2022-06-08 2022-07-29 吉林大学第一医院 一种甲基苯胺类Aβ蛋白显像剂的双柱合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000963A1 (en) * 1990-07-12 1992-01-23 Yoshitomi Pharmaceutical Industries, Ltd. Styryl compounds and use thereof as medicine
JPH0545875A (ja) * 1991-08-08 1993-02-26 Konica Corp 感光性組成物
US6020436A (en) * 1993-03-09 2000-02-01 The Chromaline Corporation Photosensitive resin composition
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
AU2001239544A1 (en) * 2000-03-22 2001-10-03 Bf Research Institute, Inc. Image diagnosis probe based on substituted azobenzene or analogue thereof for disease attributable to amyloid accumulation and composition for image diagnosis containing the same
US8007954B2 (en) 2000-11-09 2011-08-30 The Trustees Of The University Of Pennsylvania Use of sulfur-containing fuels for direct oxidation fuel cells
JP2002182254A (ja) 2000-12-18 2002-06-26 Fuji Photo Film Co Ltd 非線形光学材料とその製造方法
WO2003018070A1 (en) * 2001-08-27 2003-03-06 The Trustees Of The University Of Pennsylvania Stilbene derivatives and their use for binding and imaging amyloid plaques
CN1672283A (zh) 2002-06-06 2005-09-21 宾夕法尼亚州大学理事会 陶瓷阳极及其制造方法
AU2003258612A1 (en) * 2002-08-14 2004-03-03 4Sc Ag Pyrimidones as antiviral agents
JP4482352B2 (ja) 2004-03-11 2010-06-16 本田技研工業株式会社 固体高分子型燃料電池
AU2005316421B2 (en) * 2004-12-17 2012-04-05 The Trustees Of The University Of Pennsylvania Stilbene derivatives and their use for binding and imaging amyloid plaques
WO2006078384A2 (en) * 2004-12-17 2006-07-27 The Trustees Of The University Of Pennsylvania Stilbene derivatives and their use
WO2007002540A2 (en) * 2005-06-24 2007-01-04 Kung Hank F Radiolabeled-pegylation of ligands for use as imaging agents
ATE539060T1 (de) * 2006-03-30 2012-01-15 Univ Pennsylvania Styrylpyridinderivate und ihre verwendung zur bindung und abbildung von amyloider plaque
US20080253967A1 (en) * 2007-04-13 2008-10-16 Kung Hank F Halo-Stilbene Derivatives And Their Use For Binding And Imaging Of Amyloid Plaques

Also Published As

Publication number Publication date
HUS1300028I1 (hu) 2017-08-28
EA200870389A1 (ru) 2009-04-28
PL2363392T3 (pl) 2017-10-31
ES2628882T3 (es) 2017-08-04
EP1999109B1 (en) 2011-12-28
US20130129624A1 (en) 2013-05-23
TWI399366B (zh) 2013-06-21
PT1999109E (pt) 2012-03-16
US7687052B2 (en) 2010-03-30
EP1999109A2 (en) 2008-12-10
KR20080106564A (ko) 2008-12-08
HRP20120135T1 (hr) 2012-03-31
NO2018030I1 (no) 2018-09-11
NZ570887A (en) 2011-05-27
FR13C0034I2 (fr) 2014-03-07
US8506929B2 (en) 2013-08-13
US20080038195A1 (en) 2008-02-14
UA97802C2 (uk) 2012-03-26
TW200838852A (en) 2008-10-01
SI1999109T1 (sl) 2012-04-30
FR13C0034I1 (el) 2013-08-09
MX2008012527A (es) 2008-10-14
SI2363392T1 (sl) 2017-09-29
ZA200807955B (en) 2012-11-28
ATE539060T1 (de) 2012-01-15
BRPI0710225B1 (pt) 2021-07-13
CN101522624B (zh) 2013-11-06
HUE032660T2 (en) 2017-10-30
CA2644530C (en) 2015-05-19
ES2378785T3 (es) 2012-04-17
AU2007243712A1 (en) 2007-11-08
NO342090B1 (no) 2018-03-19
KR101376807B1 (ko) 2014-03-20
PL1999109T3 (pl) 2012-05-31
PT2363392T (pt) 2017-06-15
EP2363391A1 (en) 2011-09-07
SG173338A1 (en) 2011-08-29
EA017898B1 (ru) 2013-04-30
DK2363392T3 (en) 2017-07-03
JP5290954B2 (ja) 2013-09-18
CY1113048T1 (el) 2015-11-04
LT2363392T (lt) 2017-07-25
AU2007243712B2 (en) 2013-01-10
BRPI0710225A2 (pt) 2011-08-02
RS56171B1 (sr) 2017-11-30
HRP20170857T1 (hr) 2017-12-01
EP2363392A1 (en) 2011-09-07
IL193567A0 (en) 2009-05-04
WO2007126733A2 (en) 2007-11-08
CA2644530A1 (en) 2007-11-08
RS52222B (en) 2012-10-31
IL193567A (en) 2014-03-31
LU92232I9 (el) 2019-01-15
DK1999109T3 (da) 2012-04-02
ECSP088783A (es) 2008-10-31
NO20084590L (no) 2008-12-29
CN101522624A (zh) 2009-09-02
CY2013024I1 (el) 2015-11-04
WO2007126733A3 (en) 2008-03-06
GT200800201A (es) 2009-08-20
LU92232I2 (fr) 2013-08-26
US8840866B2 (en) 2014-09-23
US20090123369A1 (en) 2009-05-14
EP2363392B1 (en) 2017-05-03
CR10329A (es) 2008-10-29
JP2009532349A (ja) 2009-09-10
CY2013024I2 (el) 2015-11-04

Similar Documents

Publication Publication Date Title
CY1119048T1 (el) Παραγωγα στυρυλοπυριδινης και η χρηση τους για συνδεση κι απεικονιση πλακων αμυλοειδους
CY1121431T1 (el) Μορια αντισωματος που εχουν ειδικοτητα για τον ανθρωπινο οχ40
CY1121882T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CY1123901T1 (el) Φαρμακευτικη συνθεση και χορηγησεις αυτης
CY1122073T1 (el) Μορια αντισωματος που εχουν εξειδικευση για τον ανθρωπινο οχ40
CY1119618T1 (el) Ενωσεις και συνθεσεις ως ρυθμιστικα μορια της tlr δραστηριοτητας
CY1122428T1 (el) Θεραπευτικη αγωγη της παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας με διειδικα αντισωματα εναντι cd3xcd19
CY1121183T1 (el) Νεες θεραπευτικες μεθοδευσεις για θεραπευτικη αγωγη cmt και συναφων διαταραχων
CY1118454T1 (el) Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες
CY1116264T1 (el) Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2
CY1114988T1 (el) Βενζοδιαζεπινη αναστολεας bromodomain
CY1113231T1 (el) Απαραβιαστες φαρμακοτεχνικες μορφες δοσολογιας απο του στοματος περιλαμβανουσες ενα οπιουχο αναλγητικο
CY1117331T1 (el) Αντισωματα προσδεσης στην εξωκυτταρικη περιοχη 4 του ανθρωπινου csf1r και η χρηση αυτων
CY1117326T1 (el) Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson
CY1115994T1 (el) Φαρμακευτικες τυποποιησεις οι οποιες περιεχουν προσδεματα υποδοχεα ντοπαμινης
CY1115381T1 (el) Διενυδρη υδροχλωρικη ναλμεφαινη
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
CY1117995T1 (el) Δευτεριωμενα παραγωγα κατεχολαμινης και φαρμακα που περιεχουν τις εν λογω ενωσεις
CY1116064T1 (el) Συστασεις αναστολεα ddp iv
CY1112558T1 (el) Ενωσεις ν-μεθυλαμινομεθυλο ισοϊνδολης και συνθεσεις που τις περιλαμβανουν και μεθοδοι χρησης τους
CY1115254T1 (el) Φαρμακευτικα διαλυματα, διαδικασιες για την παρασκευη τους και θεραπευτικες χρησεις
CY1114669T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
CY1120852T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ιβουπροφαινη, τραμαδολη και ενα βασικο αμινοξυ, μεθοδος παρασκευης αυτης και χρηση της ιδιας
CY1122998T1 (el) Μεθοδοι και συνθεσεις για την αντιμετωπιση της καταθλιψης χρησιμοποιωντας κυκλοβενζαπρινη
CY1115081T1 (el) Νεο εκχυλισμα απο γαϊδουραγκαθο, μεθοδος για την παρασκευη και η χρηση του